The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.50
Bid: 18.50
Ask: 19.38
Change: -0.36 (-1.87%)
Spread: 0.88 (4.757%)
Open: 19.48
High: 19.48
Low: 18.50
Prev. Close: 19.30
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Nanoco Announces Major Milestone Payment

8 May 2018 07:00

RNS Number : 3060N
Nanoco Group PLC
08 May 2018
 

 

This announcement contains inside information as defined in EU Regulation No. 596/2014 and is in accordance with the Company's obligations under Article 17 of that Regulation.

 

NANOCO GROUP PLC

("Nanoco" or the "Company")

 

Nanoco Announces Major Milestone Payment from US Partner

 

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, today announces that it will receive a £1.8 million payment from its undisclosed US-listed partner (the "Partner") after recently completing an important milestone in the Material Development and Supply Agreement announced in February 2018.

 

This milestone (the second of three) has been completed in line with the timetable set out in the agreement and reflects rapid progress being made. The total value of milestones in this programme triggered to date is £2.6 million.

 

Michael Edelman, Chief Executive of Nanoco, said:

 

"We are pleased to achieve this key milestone for our US Partner, which demonstrates Nanoco's ability to work with, and rapidly meet, our partner's needs. We remain confident in meeting our timelines to begin commercial supply and in addition, delivering on the expansion of our US partnership recently announced.

 

As previously disclosed, the Partner is funding the capital expenditure required to expand the manufacturing capabilities of Nanoco's existing Runcorn facility in order to supply the Partner with commercial volumes of product. This process is already underway, with an agreement reached in March to take over 10,000 sq. ft. of additional space in Runcorn to build a state-of-the-art production facility in order to commence commercial supply in January 2019.

 

- Ends -

 

For further information, please contact:

 

MHP Communications Tel: +44 (0) 20 3128 8570

Reg Hoare / Giles Robinson / Pete Lambie

nanoco@mhpc.com 

 

The person responsible for arranging for the release of this announcement on behalf of the Company is David Blain, Chief Financial Officer.

 

 

Notes for editors:

 

About Nanoco Group plc

Nanoco (LSE: NANO) harnesses the power of nano-technology to create a brighter, more sustainable future. Based on breakthrough science, Nanoco's proprietary manufacturing process enables the large-scale production of its cadmium-free CFQD® quantum dots for multiple applications including LCD display, lighting, healthcare, nano-materials and solar.Nanoco has non-exclusive manufacturing and marketing licensing agreements in display with The Dow Chemical Company, Merck KGaA of Germany and Wah Hong Industrial Corporation of Taiwan.Nanoco was founded in 2001 and is headquartered in Manchester, UK, with a US subsidiary, Nanoco Inc., in Concord, MA. Nanoco continues to build out a world-class, patent-protected IP portfolio generated both by its own innovation engine, as well as through acquisition. Nanoco is listed on the Main Market of the London Stock Exchange and trades under the ticker symbol NANO. For further information please visit: www.nanocogroup.com. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTKMGGKKRMGRZG
Date   Source Headline
20th Jul 20237:00 amRNSNotification of Investor Presentation
18th Jul 20237:00 amRNSPosting of Circular and Notice of General Meeting
7th Jul 202311:23 amRNSGeneral Meeting - Voting Results
28th Jun 20237:00 amRNSReceipt of General Meeting Requisition Notice
20th Jun 20237:00 amRNSPosting of Circular and Notice of General Meeting
9th Jun 20237:00 amRNSBlocklisting Six-Monthly Return
19th May 20231:00 pmRNSResponse to Shareholder Letter
21st Apr 20236:00 pmRNSHolding(s) in Company
30th Mar 202311:46 amRNSHolding(s) in Company
28th Mar 20237:00 amRNSInterim Results
27th Mar 20231:19 pmRNSResponse to Shareholder Letter
23rd Mar 20238:40 amRNSNotice of Results
9th Mar 20233:11 pmRNSHolding(s) in Company
9th Feb 20237:00 amRNSDirector/PDMR Shareholding
7th Feb 20237:00 amRNSHolding(s) in Company
3rd Feb 20237:15 amRNSTrading Update
3rd Feb 20237:15 amRNSLitigation Settlement Update
18th Jan 202311:35 amRNSHolding(s) in Company
16th Jan 202312:45 pmRNSHolding(s) in Company
11th Jan 20232:40 pmRNSHolding(s) in Company
10th Jan 20232:37 pmRNSHolding(s) in Company
9th Jan 20237:00 amRNSLitigation Settlement Update
6th Jan 20237:00 amRNSLitigation Outcome – Settlement Agreed
4th Jan 20233:31 pmRNSHolding(s) in Company
20th Dec 20223:51 pmRNSHolding(s) in Company
20th Dec 20222:59 pmRNSResult of AGM
20th Dec 20227:00 amRNSAGM Statement
13th Dec 20227:00 amRNSBlock listing Six-monthly Return
9th Dec 20227:00 amRNSLitigation Update - Firm Trial Date
14th Nov 202210:46 amRNS2022 Annual Report and Notice of AGM
7th Nov 20224:13 pmRNSHolding(s) in Company
27th Oct 20225:19 pmRNSDirector/PDMR Shareholding
26th Oct 20222:31 pmRNSLitigation Update – Funded Law Suit Filed in China
20th Oct 20227:00 amRNSPreliminary Results
14th Oct 202212:59 pmRNSPresentation via Investor Meet Company
14th Oct 202210:41 amRNSNotice of Results
28th Sep 20227:00 amRNSLitigation Update – Further Revised Trial Date
12th Sep 20228:25 amRNSTrading Update & Directorate Change
7th Sep 20223:47 pmRNSLitigation Update – Revised Trial Date
1st Sep 202210:22 amRNSDirector/PDMR Shareholding
31st Aug 20227:00 amRNSTwo Grant Funding Awards
30th Aug 20223:33 pmRNSHolding(s) in Company
30th Aug 20223:28 pmRNSDirector/PDMR Shareholding
25th Aug 20221:36 pmRNSDirector/PDMR Shareholding
23rd Aug 20222:22 pmRNSFunded Law Suit Filed in Germany
19th Aug 20228:21 amRNSLitigation Update – Pre-Trial Conference
18th Aug 20224:10 pmRNSDirector/PDMR Shareholding
16th Aug 20227:00 amRNSTrading Update
28th Jul 202210:42 amRNSHolding(s) in Company
13th Jul 20222:03 pmRNSReplacement - Director/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.